Market Overview

UPDATE: Morgan Stanley Upgrades Bristol-Myers Squibb Co. on Potential of New Cancer Drugs

Related BMY
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Pamela Anderson And Hepatitis C: Which Drug Makers Are Working On A Cure?
Clinton's Price Caps Are A Non-Starter: Liana Moussatos Of Wedbush Securities (Seeking Alpha)

In a report published Monday, Morgan Stanley analyst David Risinger upgraded the rating on Bristol-Myers Squibb Co. (NYSE: BMY) from Equal-Weight to Overweight, and raised the price target from $45.00 to $60.00.

In the report, Morgan Stanley noted, “Upgrading to OW and raising PT from $45 to $60 after raising 2020E EPS by 27%; $60 PT is up 23% from Friday's close. BMY is the leading contender to transform cancer treatment with new drugs that boost the immune system.”

Bristol-Myers Squibb Co. closed on Friday at $48.77.

Latest Ratings for BMY

Sep 2015UBSUpgradesNeutralBuy
Aug 2015JefferiesMaintainsHold
Aug 2015Piper JaffrayUpgradesUnderN

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Upgrades Analyst Ratings


Related Articles (BMY)

View Comments and Join the Discussion!

Get Benzinga's Newsletters